361 results
8-K
EX-99.1
LCTX
Lineage Cell Therapeutics, Inc.
8 Aug 24
Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
4:10pm
liabilities, current portion
Deferred revenues, current portion
Total current liabilities
LONG-TERM LIABILITIES
Deferred tax liability
Deferred revenues … securities, net
Foreign currency transaction loss, net
Other income
Total other income (expenses)
LOSS BEFORE INCOME TAXES
Provision for income tax
424B5
LCTX
Lineage Cell Therapeutics, Inc.
14 May 24
Prospectus supplement for primary offering
4:36pm
and in the securities or other property receivable upon conversion or exchange; and
important U.S. federal income tax considerations.
The prospectus … issue discount,” (“OID”), for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities
8-K
EX-99.1
5fok4o o34qcl
9 May 24
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:10pm
424B5
rdlrc8 45en
22 Mar 24
Prospectus supplement for primary offering
4:32pm
8-K
EX-1.1
9s9rgc
22 Mar 24
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-99.1
in8odi4 5y8q
7 Mar 24
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:10pm
424B5
94rdabs
6 Feb 24
Prospectus supplement for primary offering
9:25am
8-K
EX-10.1
9gejv
6 Feb 24
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
9:20am
8-K
EX-99.1
ee8m1t3 e0mvbl
9 Nov 23
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm